iStock.com/Sundry Photography
Bud Light Reveals Aftermath of Controversy
February 29, 2024
In 2023, Anheuser-Busch InBev, the biggest brewer globally, faced a colossal setback, potentially losing $1.4 billion in sales due to a brief collaboration with a transgender influencer to endorse Bud Light beer.
Though reporting record revenues, AB InBev pointed out that its growth in the U.S. was limited due to a backlash triggered by a sponsored Instagram post featuring Dylan Mulvaney. Consequently, organic revenue in North America plummeted by $1.4 billion last year, mainly attributed to a decline in Bud Light sales, which forms a significant chunk of AB InBev’s revenue.
Following the partnership with Mulvaney, Bud Light sales nosedived as anti-trans sentiments stirred a boycott. The company’s lukewarm response further irked LGBTQ+ advocates. Subsequently, Modelo Especial claimed the top-selling beer spot in the U.S., ending Bud Light’s two-decade reign.
CEO Michel Doukeris acknowledged a sluggish recovery on Thursday when speaking to investors, with Bud Light regaining only 1.2 percentage points of lost market share from May 2023 to February 2024. Despite efforts, the pace remains slow, with the recovery of a mere 0.1 to 0.2 percentage points every few weeks.
Analysts criticized the underwhelming recovery, highlighting double-digit revenue declines and market share losses in the U.S.
In a separate development, AB InBev averted a potential strike by reaching a tentative agreement with the Teamsters union on Wednesday, benefiting shareholders. The strike would have seen 5,000 workers walk out at midnight on Thursday. The company remains cautiously optimistic about its U.S. business, noting a gradual improvement in market share since May.
However, AB InBev’s Asia business witnessed a setback, with Budweiser Brewing Company APAC shares dropping by nearly 7% in Hong Kong due to declining profits attributable to a one-off customs charge in South Korea. Sales volumes in China also dipped in the fourth quarter despite double-digit growth in premium brands.
The fallout from the Bud Light controversy serves as a cautionary tale, highlighting the delicate balance companies must strike when engaging with influencers in today’s social media landscape.
Recent News
Massive Data Breach Hits Ticketmaster, Affecting 560 Million Customers
Ticketmaster has fallen victim to a significant cyber-attack, potentially compromising the data of up to 560 million customers. The breach was confirmed by Ticketmaster’s parent company, Live Nation, which revealed that a notorious hacking group, ShinyHunters, is behind the attack. The hackers are demanding a ransom of approximately £400,000 to prevent the data from being sold on the dark web.
Toyota Recalls 100,000+ Tundra and Lexus LX SUVs Over Engine Debris Issue
Toyota has announced a recall for over 100,000 Tundra pickups and Lexus LX SUVs in North America due to potential engine issues caused by machining debris. This recall affects certain 2022-2023 models of the Tundra and LX, which are equipped with the new V6 twin-turbo engine. The V6 twin-turbo engine has faced considerable scrutiny regarding its reliability, especially when compared to the previous naturally aspirated V8 engines.
Wordle and Worldle Battle Over Names
A legal dispute has erupted between the wildly popular word game Wordle and the lesser-known geography game Worldle, centering on the similarity of their names. Wordle, which was developed by Josh Wardle in 2021 and later acquired by the New York Times in 2022 for a substantial sum, has gained immense popularity. In this game, players have six attempts to guess a five-letter word.
FDA Issues Recall for Crecelac Goat Milk Infant Formula
The U.S. Food and Drug Administration (FDA) has issued a safety alert regarding Crecelac Goat Milk Infant Formula and other infant formula products imported and distributed by Dairy Manufacturers Inc. The alert highlights Cronobacter contamination concerns with Crecelac Infant Powdered Goat Milk Infant Formula. Although Dairy Manufacturers Inc. initiated a recall on May 24, 2024, due to non-compliance with FDA regulations, new findings of Cronobacter contamination have prompted further action.